Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor ( α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects

ConclusionsRopanicant was found to be safe and well tolerated following single and multiple oral administrations in healthy subjects. Ropanicant showed nonlinear pharmacokinetics and accumulation following multiple dosing. Urinary excretion represents an insignificant elimination pathway for ropanicant. Ropanicant pharmacokinetics were sex dependent, and food and age had no effect on its  pharmacokinetics.Clinical Trial RegistrationNCT03155503 and NCT03551288.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research